Bart Van Wijmeersch

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients

Nele Claes, Judith Fraussen, Marjan Vanheusden et al. · The Journal of Immunology · 2016 · 207 citations · Full text

Life Sciences, Immunology, Neurology +17

Ablation of Proliferating Microglia Does Not Affect Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase

Genevíève Gowing, Thomas Philips, Bart Van Wijmeersch et al. · Journal of Neuroscience · 2008 · 144 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Circulating Follicular Regulatory T Cells Are Defective in Multiple Sclerosis

Tessa Dhaeze, Evelyn Peelen, Anneleen Hombrouck et al. · The Journal of Immunology · 2015 · 137 citations

Life Sciences, Immunology, Pathology +17